[{"orgOrder":0,"company":"Plexxikon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"PLX51107","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Oncology","graph2":"Phase I","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plexxikon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Plexxikon \/ Undisclosed"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PLX7486","moa":"Granulocyte colony-stimulating factor receptor (G-CSF-R)","graph1":"Oncology","graph2":"Phase I","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexxikon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Plexxikon \/ Undisclosed"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Cogent Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bezuclastinib","moa":"c-KIT receptor||KIT*","graph1":"Oncology","graph2":"Phase III","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plexxikon \/ Plexxikon","highestDevelopmentStatusID":"10","companyTruncated":"Plexxikon \/ Plexxikon"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"PLX5622","moa":"Macrophage colony stimulating factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexxikon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Plexxikon \/ Undisclosed"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"PLX5622","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexxikon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Plexxikon \/ Undisclosed"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexxikon \/ Plexxikon","highestDevelopmentStatusID":"8","companyTruncated":"Plexxikon \/ Plexxikon"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexxikon \/ Plexxikon","highestDevelopmentStatusID":"8","companyTruncated":"Plexxikon \/ Plexxikon"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexxikon \/ Plexxikon","highestDevelopmentStatusID":"8","companyTruncated":"Plexxikon \/ Plexxikon"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexxikon \/ Plexxikon","highestDevelopmentStatusID":"8","companyTruncated":"Plexxikon \/ Plexxikon"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Plexxikon \/ Plexxikon","highestDevelopmentStatusID":"6","companyTruncated":"Plexxikon \/ Plexxikon"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plexxikon \/ Plexxikon","highestDevelopmentStatusID":"7","companyTruncated":"Plexxikon \/ Plexxikon"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plexxikon \/ Plexxikon","highestDevelopmentStatusID":"7","companyTruncated":"Plexxikon \/ Plexxikon"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexxikon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Plexxikon \/ Undisclosed"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"PLX73086","moa":"Macrophage colony-stimulating factor 1 (CSF1)","graph1":"Oncology","graph2":"Phase I","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plexxikon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Plexxikon \/ Undisclosed"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Novellus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Plixorafenib","moa":"Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Plexxikon \/ Novellus","highestDevelopmentStatusID":"7","companyTruncated":"Plexxikon \/ Novellus"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Hannah Choe","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PLX51107","moa":"Bromodomain and extraterminal domain protein (BET)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plexxikon \/ Hannah Choe","highestDevelopmentStatusID":"7","companyTruncated":"Plexxikon \/ Hannah Choe"},{"orgOrder":0,"company":"Plexxikon","sponsor":"Hope Rugo","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Pexidartinib","moa":"Macrophage colony stimulating factor receptor | Tyrosine-protein kinase receptor FLT3 | Stem cell growth factor receptor||Tyrosine-protein kinase receptor FLT3 | Macrophage colony stimulating factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Plexxikon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Plexxikon \/ Hope Rugo","highestDevelopmentStatusID":"7","companyTruncated":"Plexxikon \/ Hope Rugo"}]
Find Clinical Drug Pipeline Developments & Deals by Plexxikon
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
